Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

BioAmber Inc. BIOAQ

BioAmber Inc is an industrial biotechnology company producing renewable chemicals. The company's proprietary technology platform combines industrial biotechnology and chemical catalysis to convert bio-based feedstocks into renewable chemicals that are cost-competitive replacements for petroleum-derived chemicals used in a wide variety of everyday products including plastics, resins, paints, food additives and personal care products. BioAmber produces bio-succinic acid at a facility in Sarnia, On


OTCPK:BIOAQ - Post by User

Post by dns236on Jan 30, 2017 7:17am
709 Views
Post# 25771115

BioAmber Announces Reimbursement Of Corporate Debt

BioAmber Announces Reimbursement Of Corporate Debt
BioAmber announces reimbursement of corporate debt and closing of public offering
07:00 EST Monday, January 30, 2017 
MONTREAL, Jan. 30, 2017 /CNW Telbec/ - BioAmber Inc. (NYSE: BIOA) is pleased to announce that on January 27th the Company reimbursed its CDN$25 million loan (approximately US$19.3 million) with Bridging Finance Inc.  Following the repayment of this loan, BioAmber has no corporate debt.
 
On January 27 th, 2017 BioAmber also closed on its previously announced public offering of 3,684,212 shares of common stock together with warrants to purchase 1,842,106 shares of common stock, at a price to the public of US$4.75 per share and associated warrant, as well as the full exercise of the underwriters' option to purchase an additional 552,632 shares of common stock and additional warrants to purchase 276,316 shares of common stock.  The gross proceeds from the offering were US$20.1 million and the expected net proceeds are approximately US$18.6 million, after deducting Company expenses, underwriting discounts and commissions.  The warrants are exercisable at a price of US$5.50 per share of common stock, have a term of four years, and are exercisable upon the date of issuance.  A portion of these securities was issued in Canada on a private placement basis. Rodman & Renshaw, a unit of H.C. Wainwright & Co., acted as the sole book-running manager in connection with this offering and AltaCorp Capital, Cormark Securities and Clarus Securities acted as co-managers.
 
Copies of the prospectus supplement and the accompanying base prospectus related to the offering may be obtained for free by visiting EDGAR on the Securities and Exchange Commission's website at www.sec.gov.  Alternatively, copies of the prospectus and the prospectus supplement relating to the offering may be obtained from H.C. Wainwright & Co., LLC, 430 Park Avenue, New York, NY 10022, by calling 646-975-6996 or by email at placements@hcwco.com.
 
About BioAmber
BioAmber (NYSE: BIOA) is a renewable materials company. Its innovative technology platform combines biotechnology and catalysis to convert renewable feedstock into building block materials that are used in a wide variety of everyday products including plastics, paints, textiles, food additives and personal care products.  For more information visit www.bio-amber.com.
<< Previous
Bullboard Posts
Next >>